Q10 therapy in patients with idiopathic Parkinson's disease

Molecular Aspects of Medicine

Volumn 18, Issue SUPPL., 1997, Pages 237-240

  Strijks, E ^a   Kremer, H P H ^a   Horstink, M W I M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Coenzyme Q10; Neuroprotection; Parkinson's disease; Therapy

Indexed keywords

UBIDECARENONE; ANTIOXIDANT; DRUG DERIVATIVE; NEUROPROTECTIVE AGENT; UBIQUINONE;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; IDIOPATHIC DISEASE; MOTOR PERFORMANCE; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; AGED; ARTICLE; DRUG EFFECT; HOSPITALIZATION; MIDDLE AGED; PSYCHOMOTOR PERFORMANCE;

AGED; ANTIOXIDANTS; HUMANS; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; SEVERITY OF ILLNESS INDEX; UBIQUINONE;

EID: 0030626791     PISSN: 00982997     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0098-2997(97)00008-3     Document Type: Conference Paper

References (17)

1. 10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Annals of Neurology, 36, 882-888.
2. 31P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies. Neurology, 42, 1203-1208.
3. 10. Neurology, 38, 892-899.
4. Edlund, C., Soderberg, M. and Kristensson, K. (1994). Isoprenoids in aging and neurodegeneration. Neurochemistry International, 25, 35-38.
5. Fariello, R. G., Ghilardi, O., Peschechera, A., Ramacci, M. T. and Angelucci, L. (1988). Regional distribution of ubiquinones and tocopherols in the mouse brain: lowest content of ubiquinols in the substantia nigra. Neuropharmacology, 27, 1077-1080.
6. Favit, A., Nicoletti, F., Scapagnini, U. and Canonico, P. L. (1992). Ubiquinone protects cultured neurons against spontaneous and excitotoxin induced degeneration. Journal of Cerebral Blood Flow and Metabolism, 12, 638-645.
7. 10 tolerability in Huntington's disease. Mov Dis, 11, 321-323.
8. Hartley, A., Stone, J. M., Heron, C., Cooper, J. M. and Schapira, A. H. (1994). Complex I inhibitors induce dose dependent apoptosis in PC12 cells: relevance to Parkinson's disease. Journal of Neurochemistry, 63, 1987-1990.
9. Horstink, M. W. I. M., Zijlmans, J. C. M., Pasman, J. W., Berger, H. J. C., Korten, J. J. and van't Hof, M. A. (1990). Which risk factors predict the Levodopa response in fluctuating Parkinson's disease? Annals of Neurology, 27, 537-543.
10. Koroshetz, W. J., Jenkins, B. and Rosen, B. (1993). Ubiquinone lowers occipital lactate levels in patients with Huntington's disease. Neurology, 43, suppl 4, 334
11. Marsden, C. D. (1994). Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 57, 672-681.
12. 10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology, 43, 884-890.
13. Schapira, A. H. V., Mann, V. M., Cooper, J. M., Dexter, D., Daniel, S. E., Jenner, P., Clark, J. B. and Marsden, C. D. (1990). Anatomic and disease specificity of NADH-CoQ1 reductase (complex 1) deficiency in Parkinson's disease. Journal of Neurochemistry, 55, 2142-2145.
14. Schneider, H., Lemaster, J. J. and Hackembroek, C. R. (1982). Lateral diffusion of ubiquinone during electron transport in phospholipid-and ubiquinone-enriched mitochondrial membrane. Journal of Biological Chemistry, 257, 10789-10793.
15. 10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Experimental Neurology, 132, 279-283.
16. Singer, T. P., Ramsay, R. R., McKeown, K., Trevor, A. and Castagnoli, N. E. (1988). Mechanism of the neurotoxicity of 1-methyl-4-phenylpyridinium (MPP+), the toxic bioactivation product of MPTP. Toxicology, 49, 17-23.
17. Tipton, K. F. and Singer, T. P. (1993). Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compunds. Journal of Neurochemistry, 61, 1191-1206.